JP2025501630A5 - - Google Patents
Info
- Publication number
- JP2025501630A5 JP2025501630A5 JP2024538682A JP2024538682A JP2025501630A5 JP 2025501630 A5 JP2025501630 A5 JP 2025501630A5 JP 2024538682 A JP2024538682 A JP 2024538682A JP 2024538682 A JP2024538682 A JP 2024538682A JP 2025501630 A5 JP2025501630 A5 JP 2025501630A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- heterocycloalkyl
- cycloalkyl
- hydrogen
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021904274 | 2021-12-24 | ||
| AU2021904274A AU2021904274A0 (en) | 2021-12-24 | Compounds | |
| PCT/AU2022/051593 WO2023115167A1 (en) | 2021-12-24 | 2022-12-23 | Compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501630A JP2025501630A (ja) | 2025-01-22 |
| JP2025501630A5 true JP2025501630A5 (enExample) | 2026-01-07 |
Family
ID=86900852
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538682A Pending JP2025501630A (ja) | 2021-12-24 | 2022-12-23 | 化合物 |
| JP2024538674A Pending JP2025501629A (ja) | 2021-12-24 | 2022-12-23 | 化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538674A Pending JP2025501629A (ja) | 2021-12-24 | 2022-12-23 | 化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20250074873A1 (enExample) |
| EP (2) | EP4452937A4 (enExample) |
| JP (2) | JP2025501630A (enExample) |
| CN (2) | CN118715204A (enExample) |
| CA (2) | CA3244229A1 (enExample) |
| WO (2) | WO2023115167A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| KR102946120B1 (ko) | 2019-02-27 | 2026-03-30 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클 |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| WO2022221415A2 (en) | 2021-04-13 | 2022-10-20 | The Regents Of The University Of California | Tetracyclic compounds for treating brain disorders |
| EP4396162A4 (en) | 2021-09-03 | 2025-11-12 | Alexander Shulgin Res Institute Inc | ASYMMETRIC ALLYL TRYPTAMINES |
| JP2025502615A (ja) | 2021-12-15 | 2025-01-28 | デリックス セラピューティクス，インク． | フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用 |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| CA3253725A1 (en) * | 2022-05-20 | 2023-11-23 | Caamtech, Inc. | TRYPTAMINE DERIVATIVES |
| AU2023323907A1 (en) * | 2022-08-11 | 2025-02-20 | Gilgamesh Pharmaceuticals, Inc. | Tryptamines and methods of treating mood disorders |
| CA3265884A1 (en) * | 2022-08-31 | 2024-03-07 | Cybin Irl Limited | TRYPTAMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE |
| CN121866243A (zh) * | 2023-09-07 | 2026-04-14 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 致幻化合物、其制备方法及其用途 |
| WO2025137581A1 (en) * | 2023-12-21 | 2025-06-26 | Atai Therapeutics, Inc. | Novel tetrahydro pyridine substituted indole and azaindoles, compositions of matter and pharmaceutical compositions |
| US12679847B1 (en) | 2025-08-04 | 2026-07-14 | Nalu Bio, Inc. | Aryl-substituted n-alkyl indoles and their use as pharmacologically active agents |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1928892A (en) * | 1991-06-21 | 1993-01-25 | Smithkline Beecham Plc | Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists |
| GB9718833D0 (en) * | 1997-09-04 | 1997-11-12 | Merck Sharp & Dohme | Therapeutic agents |
| AU767009B2 (en) * | 1998-12-11 | 2003-10-30 | Virginia Commonwealth University | Selective 5-HT6 receptor ligands |
| SI1379239T1 (sl) * | 2001-03-29 | 2008-02-29 | Lilly Co Eli | N-(2-ariletil)benzilamini, uporabljeni kot antagonisti receptorja 5-ht6 |
| KR20050010512A (ko) * | 2002-06-12 | 2005-01-27 | 스미또모 세이야꾸 가부시키가이샤 | 인돌, 인다졸 및 벤즈아졸류 |
| CA2508290C (en) * | 2002-12-20 | 2017-02-28 | Ciba Specialty Chemicals Holding Inc. | Synthesis of amines and intermediates for the synthesis thereof |
| ES2564804T3 (es) * | 2004-02-12 | 2016-03-29 | Mitsubishi Tanabe Pharma Corporation | Compuesto de indazol y uso farmacéutico del mismo |
| WO2006047032A2 (en) * | 2004-09-27 | 2006-05-04 | Organix, Inc. | Indole compounds useful as serotonin selective agents |
| WO2007046112A1 (en) * | 2005-10-19 | 2007-04-26 | Suven Life Sciences Inc. | Arylthioether tryptamine derivatives as functional 5-ht6 ligands |
| WO2008046155A1 (en) * | 2006-10-20 | 2008-04-24 | Dia-B Tech Limited | Methods for regulating glucose homeostasis and agents therefor |
| US20090318527A1 (en) * | 2008-02-11 | 2009-12-24 | Howard Sard | Indole compounds and methods of use thereof |
| BRPI0916395A2 (pt) * | 2008-07-30 | 2016-02-16 | Ferrer Int | compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno |
| US8349898B2 (en) * | 2008-11-18 | 2013-01-08 | Wisconsin Alumni Research Foundation | Sigma-1 receptor ligands and methods of use |
| US8912220B2 (en) * | 2009-08-10 | 2014-12-16 | Galenea Pharmaceuticals | Compounds and methods of use thereof |
| CN103601683B (zh) * | 2010-04-16 | 2016-03-30 | 中国科学院上海药物研究所 | 苯并杂环类化合物及其制备方法和用途 |
| USRE47009E1 (en) * | 2011-02-01 | 2018-08-28 | The Children's Hospital Of Philadelphia | HDAC inhibitors and therapeutic methods using the same |
| LT4084791T (lt) * | 2020-02-18 | 2025-02-25 | Gilgamesh Pharmaceuticals, Inc. | Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti |
| WO2021179091A1 (en) * | 2020-03-12 | 2021-09-16 | Bright Minds Biosciences Inc. | 3-(2-(aminoethyl)-indol-4-ol derivatives, methods of preparation thereof, and the use as 5-ht2 receptor modulators |
| IL312785B2 (en) * | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| US20230014907A1 (en) * | 2020-06-12 | 2023-01-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| WO2022246554A1 (en) * | 2021-05-26 | 2022-12-01 | Bright Minds Biosciences Inc. | Heterocyclic compounds and methods of preparation thereof |
-
2022
- 2022-12-23 CA CA3244229A patent/CA3244229A1/en active Pending
- 2022-12-23 US US18/723,836 patent/US20250074873A1/en active Pending
- 2022-12-23 EP EP22908928.9A patent/EP4452937A4/en active Pending
- 2022-12-23 JP JP2024538682A patent/JP2025501630A/ja active Pending
- 2022-12-23 CN CN202280091813.9A patent/CN118715204A/zh active Pending
- 2022-12-23 US US18/723,719 patent/US20250101038A1/en active Pending
- 2022-12-23 EP EP22908929.7A patent/EP4452938A4/en active Pending
- 2022-12-23 CN CN202280091811.XA patent/CN118696029A/zh active Pending
- 2022-12-23 WO PCT/AU2022/051593 patent/WO2023115167A1/en not_active Ceased
- 2022-12-23 WO PCT/AU2022/051592 patent/WO2023115166A1/en not_active Ceased
- 2022-12-23 JP JP2024538674A patent/JP2025501629A/ja active Pending
- 2022-12-23 CA CA3244224A patent/CA3244224A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025501629A5 (enExample) | ||
| JP2025501141A5 (enExample) | ||
| IL295371A (en) | Psilocyin derivatives as serotonergic psychedelics for the treatment of central nervous system disorders | |
| JP2023513679A5 (enExample) | ||
| JP2023512821A5 (enExample) | ||
| JP6839104B2 (ja) | ウイルス感染の治療及び予防のための新規な置換アミノチアゾロピリミジンジオン | |
| ES2729630T3 (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina D1 | |
| JP5969993B2 (ja) | 式（Ｉ）のｐａｎ−ＣＤＫ阻害剤の調製のための方法、および該調製における中間体 | |
| RU2018115569A (ru) | Оксаспиропроизводное, способ его получения и его применения в лекарственных средствах | |
| AU2022201929A1 (en) | Inhibitors of (alpha-v)(beta-6) integrin | |
| CN111171047B (zh) | 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物 | |
| JP2024508922A5 (enExample) | ||
| JP2019505541A5 (enExample) | ||
| EP3519816A1 (en) | Compounds for increasing neural plasticity | |
| CA2683887A1 (en) | Aminodihydrothiazine derivatives substituted with a cyclic group having inhibitory activity against production of amyloid beta protein | |
| CN107018661B (zh) | 6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其作为MGLUR2受体的负向别构调节剂的用途 | |
| KR20150138214A (ko) | (1s,4s,5s)-4-브로모-6-옥사비시클로[3.2.1]옥탄-7-온의 제조 방법 | |
| JP2023553094A5 (enExample) | ||
| CA3244224A1 (en) | COMPOUNDS | |
| KR20200096570A (ko) | 알츠하이머병과 같은 타우 응집체와 연관된 장애의 치료, 완화 또는 예방을 위한 1,3,4,5-테트라히드로-2h-피리도[4,3-b]인돌 유도체 | |
| JP2017536399A5 (enExample) | ||
| JP2023552610A5 (enExample) | ||
| JP2019534327A5 (enExample) | ||
| CA3002801A1 (en) | Aminoisoxazoline compounds as agonists of alpha7-nicotinic acetylcholine receptors | |
| JP2024534572A5 (enExample) |